Friday, August 25, 2023 NIAID Study Shows Low-Dose Marburg Vaccine Effective in Macaques Caption: This colorized transmission electron micrograph shows two Marburg virus particles in green. (NIAID) NIAID scientists are continuing to hone the optimal dose and inoculation timing for a promising experimental vaccine against Marburg virus, for which there is no licensed preventive vaccine. The VSV-MARV vaccine, which is in clinical development, is based on the same concept as ERVEBO, an FDA-approved vaccine against related Ebola virus. In a new study published in Emerging Microbes and Infections, scientists from NIAID's Laboratory of Virology determined in cynomolgus macaques that a low dose given two weeks before virus exposure provided robust protection; vaccination one week prior to virus exposure provided limited protection. Previously the group had determined that high doses of the vaccine were effective. With portions of Africa experiencing multiple Marburg virus outbreaks in 2023, the scientists encourage clinical evaluation of the low-dose VSV-MARV vaccine in preparation for upcoming outbreaks. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107